Understanding patient and physician experiences and attitudes toward care in Takayasu arteritis.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study uses two separate anonymous online questionnaires—one for patients (about 25 minutes) and one for physicians (about 15 minutes)—with multiple-choice and short-answer questions. Patient questions cover symptoms, treatments received, and concerns or priorities, while physician questions address diagnosis, treatment choices, and management challenges. Participation is limited to UK-based adults with a formal TAK diagnosis and physicians involved in their care. The goal is to compare patient and clinician perspectives to identify gaps and priorities in TAK care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For the patient questionnaire:

* Age ≥ 18 years
* A formal diagnosis of TAK

For the physician questionnaire

• A physician involved in the management/decision-making for patients diagnosed with TAK

Exclusion Criteria:

For the patient questionnaire:

* Age \< 18 years
* Lack of a formal diagnosis of TAK
* Patients without mental capacity or willingness to provide informed consent
* Not UK based

For the physician questionnaire

* Not involved in the management/ decision making for patients diagnosed with TAK
* Not willing to take part
* Not UK based

Where it's running

• University of Edinburgh
  Edinburgh, United Kingdom Recruiting

Study contacts

• Study coordinator: Alexandra Armstrong
• Email: A.Armstrong-9@sms.ed.ac.uk
• Phone: +447445695898

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Global Takayasu Arteritis Registry (GITA)

  The registry will collect past and ongoing medical information from people with Takayasu arteritis worldwide to see which treatments and patient features relate to better outcomes.

  Recruiting at 2 sites Marmara University · Istanbul, Istanbul and 1 other locations · NCT07558382

• Stopping biologic therapy in Takayasu arteritis patients in long-term remission

  This study will try stopping biologic medicines (TNF inhibitors or tocilizumab) in people with Takayasu arteritis who have been in clinical and imaging remission for at least three years to see if remission lasts for 12 months.

  Recruiting Marmara University · Istanbul · NCT07491913

• Comparing physical and psychosocial health in people with Takayasu arteritis, Behçet's disease, and healthy adults

  This will test whether adults with Takayasu arteritis or Behçet's disease have weaker respiratory and limb muscles, lower exercise capacity, or different quality of life and psychological well‑being compared with healthy adults.

  Recruiting Alanya Alaaddin Keykubat University · Denizli, Denizli · NCT07276087

• Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases

  This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.

  Recruiting at 2 sites Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo and 1 other locations · NCT07087912

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• Blocking endothelin to improve blood vessel function in large vessel vasculitis

  This study is testing if a medication called Bosentan can improve blood vessel function in people with large vessel vasculitis who have been in remission for at least six months.

  Recruiting Phase 2 University of Edinburgh · Edinburgh · NCT06887062

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.